CVS/pharmacy pays $77.6M settlement to DEA

CVS/pharmacy reached an agreement with the U.S. Drug Enforcement Administration and the U.S. Attorneys Offices to pay $77.6 million for failing to properly monitor the sales of pseudoephedrine, a key ingredient in the making of crystal meth. CVS/pharmacy will pay $75 million in civil penalties and $2.6 million in profit forfeitures, and agrees to comply with laws monitoring the sale of pseudoephedrine, according to a statement from the company. Flawed implementation of an electronic monitoring system resulted in excessive sales of pseudoephedrine, which is an ingredient in cold and cough medicines and in popular over-the-counter medicines. The settlement does